In the current study we demonstrated by genomic screening that CD44 expression is enhanced in aggressive (vasculogenic, VM+) tumor cells, as compared to non-aggressive (non-vasculogenic, VM−) tumor cells derived from both Ewing sarcoma and breast carcinoma tissues. This evidence concerns the gene CD44 and Ewing sarcoma.